Cas:1384441-62-6 (3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide manufacturer & supplier

We serve Chemical Name:(3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide CAS:1384441-62-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide

Chemical Name:(3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide
CAS.NO:1384441-62-6
Synonyms:(3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide
Molecular Formula:C42H71N5O22S
Molecular Weight:N/A
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide Use and application,(3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide technical grade,usp/ep/jp grade.


Related News: Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs. (3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide manufacturer These include: high-barrier generic drug substances and commonly used generic drug substances. (3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide supplier The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. (3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide vendor These include: high-barrier generic drug substances and commonly used generic drug substances. (3aS,4S,6aR)-N-[6-[[3-[[O-(N-Acetyl-alpha-neuraminosyl)-(2-6)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]propyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide factory The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years.